Case 24-80040-sgj11 Doc 910 Filed 11/10/25 Entered 11/10/25 13:47:12 Decr Main Document Page 1 01 10 UNITED STATES BANKRUPTCY COURT

Northe	ern DISTRICT OF <u>Texas</u>	
In re: Eiger BioPharmaceuticals, Inc.	\$ Case No. <u>24-80040</u> \$ Lead Case No. <u>24-80040</u>	
Debtor(s)	S	
Post-confirmation Report	Chap	oter 11
Quarter Ending Date: 09/30/2025	Petition Date: <u>04/01/2024</u>	
Plan Confirmed Date: 09/05/2024	Plan Effective Date: 09/30/2024	
This Post-confirmation Report relates to: Reorg	Authorized Party or Entity: Name of Authorized Party or Entity	-
/s/ Joshua Nahas	Joshua Nahas	
Signature of Responsible Party 11/11/2025	Printed Name of Responsible Party	
Date	10 Bank St, Suite 1100 White Plains, New York 10606 Address	

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.



Case 24-80040-sgj11 Doc 910 Filed 11/19/25 Entered 11/19/25 13:47:12 Desc Main Document Page 2 of 10

Debtor's Name Eiger BioPharmaceuticals, Inc.

Case No. 24-80040

Part 1: Summary of Post-confirmation Transfers Current Quarter a. Total cash disbursements S0 \$3,240,972

b. Non-cash securities transferred	\$0	\$0
c. Other non-cash property transferred	\$0	\$0
d. Total transferred (a+b+c)	\$0	\$3,240,972

	firmation Professional Fees and		Approved Current	Approved Cumulative	Paid Current Quarter	Paid Cumulati
Profess incurre	ional fees & expenses (bankruptcy) d by or on behalf of the debtor	Aggregate Total	\$0	\$14,404,360	\$0	\$14,404,
	ed Breakdown by Firm					
	Firm Name	Role				
i	Alvarez & Marsal	Financial Professional	\$0	\$3,452,114	\$0	\$3,452
ii	KCC, LLC	Other	\$0	\$953,110	\$0	\$953
iii	Sidley Austin LLP	Lead Counsel	\$0	\$8,331,110	\$0	\$8,331
iv	SSG Advisors, LLC	Other	\$0	\$155,031	\$0	\$155
v	Porzio, Bromberg & Newman, I	Co-Counsel	\$0	\$978,267	\$0	\$978
vi	McKool Smith PC	Co-Counsel	\$0	\$452,130	\$0	\$452
vii	Dundon Advisers LLC	Financial Professional	\$0	\$82,598	\$0	\$82
viii						
ix						
x						
xi						
xii						
xiii						
xiv						
xv						
xvi						
xvii						
xviii						
xix						
xx						
xxi						
xxii						
xxiii						
xxiv						
xxv						
xxvi						
xxvii						
xxviii						
xxix						

Case 24-80040-sgj11 Doc 910 Filed 11/19/25 Entered 11/19/25 13:47:12 Desc Main Document Page 3 of 10

 $Debtor's\ Name\ Eiger\ BioPharmaceuticals,\ Inc.$

XXX					
xxxi					
xxxii					
xxxiii					
xxxiv					
xxxv					
xxxvi					
xxxvii					
xxxviii					
xxxix					
xl					
xli					
xlii					
xliii					
xliv					
xlv					
xlvi					
xlvii					
xlviii					
xlix					
1					
li					
lii					
liii					
liv					
lv					
lvi					
lvii					
lviii					
lix					
lx					
lxi					
lxii					
lxiii					
lxiv					
lxv					
lxvi					
lxvii					
lxviii					
lxix					
lxx					
lxxi					
	l	l	l	l	L

Case 24-80040-sgj11 Doc 910 Filed 11/ Main Document Filed 11/19/25 Entered 11/19/25 13:47:12 Descoument Page 4 of 10

Debtor's Name Eiger BioPharmaceuticals, Inc.

lxxii			
lxxiii			
lxxiv			
lxxv			
lxxvi			
lxxvii			
lxxviii			
lxxix			
lxxx			
lxxxi			
lxxxii			
lxxxiii			
lxxxiv			
lxxxv			
lxxxvi			
lxxxvii			
lxxxvii			
lxxxix			
хс			
xci			
xcii			
xciii			
xciv			
xcv			
xcvi			
xcvii			
xcviii			
xcix			
С			
ci			

				Approved Current	Approved Cumulative	Paid Current Quarter	Paid Cumulative
b.	Profes	sional fees & expenses (nonbankrupto ed by or on behalf of the debtor	y) Aggregate Total				
	Itemized Breakdown by Firm						
		Firm Name	Role				
	i						
	ii						
	iii						
	iv						
	v						
	vi						

Case 24-80040-sgj11 Doc 910 Filed 11/19/25 Entered 11/19/25 13:47:12 Desc Main Document Page 5 of 10

Debtor's Name Eiger BioPharmaceuticals, Inc.

vii			
viii			
ix			
х			
xi			
xii			
xiii			
xiv			
xv			
xvi			
xvii			
xviii			
xix			
xx			
xxi			
xxii			
xxiii			
xxiv			
xxv			
xxvi			
xxvii			
xxviii			
xxix			
xxx			
xxxi			
xxxii			
xxxiii			
xxxiv			
XXXV			
xxxvi			
xxxvii			
xxxviii			
xxxix			
xl			
xli			
xlii			
xliii			
xliv			
xlv			
xlvi			
xlvii			
xlviii			

Case 24-80040-sgj11 Doc 910 Filed 11/19/25 Entered 11/19/25 13:47:12 Desc Main Document Page 6 of 10

Debtor's Name Eiger BioPharmaceuticals, Inc.

xlix			
l			
li			
lii			
liii			
liv			
lv			
lvi			
lvii			
lviii			
lix			
lx			
lxi			
lxii			
lxiii			
lxiv			
lxv			
lxvi			
lxvii			
lxviii			
lxix			
lxx			
lxxi			
lxxii			
lxxiii			
lxxiv			
lxxv			
lxxvi			
lxxvii			
lxxviii			
lxxix			
lxxx			
lxxxi			
lxxxii			
lxxxiii			
lxxxiv			
lxxxv			
lxxxvi			
lxxxvii			
lxxxvii			
lxxxix			
xc			

Case 24-80040-sgj11 Doc 910 Filed 11/19/25 Entered 11/19/25 13:47:12 Desc Main Document Page 7 of 10

Debtor's Name Eiger BioPharmaceuticals, Inc.

xci				
xcii				
xciii				
xciv				
xcv				
xcvi				
xcvii				
xcviii				
xcix				
С				
ci				
All profe	essional fees and expenses (deb	tor & committees)		

Part 3: Recoveries of the Holders of Claims and Interests under Confirmed Plan	

	Total Anticipated Payments Under Plan	Paid Current Quarter	Paid Cumulative	Allowed Claims	% Paid of Allowed Claims
a. Administrative claims	\$0	\$0	\$0	\$0	0%
b. Secured claims	\$0	\$0	\$0	\$0	0%
c. Priority claims	\$0	\$0	\$0	\$0	0%
d. General unsecured claims	\$0	\$0	\$0	\$0	0%
e. Equity interests	\$0	\$0	\$0		

Part 4: Questionnaire		
a. Is this a final report?	Yes O No •	
If yes, give date Final Decree was entered:		
If no, give date when the application for Final Decree is anticipated:		
b. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930?	Yes No	

Case 24-80040-sgj11 Doc 910 Filed 11/19/25 Entered 11/19/25 13:47:12 Desc Main Document Page 8 of 10

Debtor's Name Eiger BioPharmaceuticals, Inc.


Case No. 24-80040

Privacy Act Statement


28 U.S.C. § 589b authorizes the collection of this information and provision of this information is mandatory. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a) (6) and to otherwise evaluate whether a reorganized chapter 11 debtor is performing as anticipated under a confirmed plan. Disclosure of this information may be to a bankruptcy trustee when the information is needed to perform the trustee's duties, or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." *See* 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case, or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Post-confirmation Report and its attachments, if any, are true and correct and that I have been authorized to sign this report.


/s/ Joshua Nahas	Joshua Nahas
Signature of Responsible Party	Printed Name of Responsible Party
Plan Administrator	11/11/2025
Title	Date



Page 1




Other Page 1




Page 2 Minus Tables


Bankruntov Table 1-50




Bankruptcy Table 51-100



Non-Bankruptcy Table 1-50



Non-Bankruptcy Table 51-100



Part 3. Part 4. Last Page